Korea University Reports Findings in Esophageal Cancer (Statins and the risk of gastric, colorectal, and esophageal cancer incidence and mortality: a cohort study based on data from the Korean national health insurance claims database): Oncology – Esophageal Cancer

2022 JUN 22 (NewsRx) -- By a News Reporter-Staff News Editor at Information Technology Business Daily -- New research on Oncology - Esophageal Cancer is the subject of a report. According to news reporting originating in Seoul, South Korea, by NewsRx journalists, research stated, “This study investigated the association between the use of statins, the incidence of gastric, colorectal, and esophageal cancers, and mortality between January 2005 and June 2013 in South Korea. We compared patients aged 45-70 years statin users for at least 6 months to non-statin users matched by age and sex, from 2004 to June 2013 using the National Health Insurance database.”

The news reporters obtained a quote from the research from Korea University, “Main outcomes were gastric, colorectal, and esophageal cancer incidence and mortality. Cox proportional hazard regression was used to calculate the adjusted hazard ratios (aHRs) and 95% confidence intervals (95% CIs) among overall cohort and matched cohort after propensity score matching with a 1:1 ratio. Out of 1,008,101 people, 20,473 incident cancers, 3938 cancer deaths occurred and 7669 incident cancer, 1438 cancer death in matched cohort. The aHRs for the association between the risk of cancers and statin use were 0.7 (95% CI 0.65-0.74) for gastric cancer, 0.73 (95% CI 0.69-0.78) for colorectal cancer, and 0.55 (95% CI 0.43-0.71) for esophageal cancer. There were associations between statin use and decreased gastric cancer mortality (HR 0.46, 95% CI 0.52-0.57), colorectal cancer mortality (HR 0.43, 95% CI 0.36-0.51), and esophageal cancer mortality (HR 0.41, 95% CI 0.27-0.50) in the overall cohort and this pattern was similar in the matched cohort.”

According to the news reporters, the research concluded: “Statin use for at least 6 months was significantly associated with a lower risk of stomach, colorectal, and esophageal cancer incidence as well as cancer mortality after a diagnosis.”

This research has been peer-reviewed.

For more information on this research see: Statins and the risk of gastric, colorectal, and esophageal cancer incidence and mortality: a cohort study based on data from the Korean national health insurance claims database. Journal of Cancer Research and Clinical Oncology, 2022. Journal of Cancer Research and Clinical Oncology can be contacted at: Springer, One New York Plaza, Suite 4600, New York, Ny, United States. (Springer - www.springer.com; Journal of Cancer Research and Clinical Oncology - http://www.springerlink.com/content/0171-5216/)

Our news correspondents report that additional information may be obtained by contacting Hyun Jung Kim, Dept. of Preventive Medicine, College of Medicine, Korea University, 126-1, 5-ga, Anam-dong, Sungbuk-gu, Seoul, 136-705, South Korea. Additional authors for this research include Dong-Sook Kim and Hyeong Sik Ahn.

The direct object identifier (DOI) for that additional information is: https://doi.org/10.1007/s00432-022-04075-1. This DOI is a link to an online electronic document that is either free or for purchase, and can be your direct source for a journal article and its citation.

The publisher of the Journal of Cancer Research and Clinical Oncology can be contacted at: Springer, One New York Plaza, Suite 4600, New York, Ny, United States.

(Our reports deliver fact-based news of research and discoveries from around the world.)